Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.

Authors :: Miyazaki K
Sakai R
Iwaki N
Yamamoto G
Murayama K
Nishikori M
Sunami K
Yoshida I
Yano H
Takahashi N
Okamoto A
Munemoto S
Sawazaki A
Suehiro Y
Fukuhara N
Wake A
Arai A
Masaki Y
Toyama K
Yokoyama A
Tsunemine H
Hasegawa Y
Matsumoto K
Yamada T
Nishimura Y
Tamaru S
Asano N
Miyawaki K
Izutsu K
Kinoshita T
Suzuki R
Ohshima K
Kato K
Katayama N
Yamaguchi M
Source :: Cancer science [Cancer Sci] 2023 Jun; Vol. 114 (6), pp. 2689-2691. Date of Electronic Publication: 2023 Mar 16.
Publication Year :: 2023

Subjects :: Humans
Follow-Up Studies
Rituximab therapeutic use
Cyclophosphamide therapeutic use
Etoposide therapeutic use
Doxorubicin therapeutic use
Prednisone adverse effects
Vincristine adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Lymphoma, Large B-Cell, Diffuse drug therapy

Full Text Access

Tools